New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Brand Name :
N/A
Synonyms :
fluspirilene
Class :
Antipsychotics
Dosage Forms & StrengthsÂ
Intramuscular injectionÂ
2 mgÂ
10 mgÂ
parenteral injectionÂ
12 mgÂ
1.5 mg
Initially, 2 mg weekly through deep intramuscular injection. The dose may be increased based on the patient's response. Maintenance dose: 1-10 mg weekly.
Safety and efficacy were not establishedÂ
Refer to the adult dosing regimenÂ
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may have an increased hyperkalemia when combined with acemetacin
may have an increasingly adverse effects when combined with acenocoumarol
may have an increased CNS depression when combined with acetazolamide
may have an increased CNS depression when combined with alfentanil
may have an increased serotonin syndrome when combined with amantadine
may have an increasingly adverse effects when combined with almotriptan
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may have an increased hyperkalemia when combined with amiloride
may have an increasingly adverse effects when combined with benzatropine
may have an increased CNS depression when combined with bupivacaine
may have an increased CNS depression when combined with bromperidol
it increases the toxicity of antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
amisulpiride: they may increase the toxic effect of antipsychotic agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may increase the effect of beta-blockers
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may have an increasingly adverse effects when combined with cabergoline
may have an increased CNS depression when combined with cariprazine
may have an increasingly adverse effects when combined with carisoprodol
may have an increased CNS depression when combined with cetirizine
may have an increasingly adverse effects when combined with chlorpheniramine
may have an increased QTc prolongation when combined with chloroquine
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
fluspirilene: it may increase the hypotensive activities of spirapril
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
eprosartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
valsartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
may decrease the therapeutic effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
it increases the toxicity of antipsychotic agents
may increase the arrhythmogenic effect of Inhalational Anaesthetics
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may have an increasingly adverse effect when combined with amphetamines
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may diminish the absorption when combined
metyrosine: they may increase the toxic effect of antipsychotic agents
may decrease the therapeutic effect of each other when combined
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Could potentially amplify the neurotoxicity of antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
itopride: they may increase the neurotoxic effect of antipsychotic agents
silodosin: they may decrease the therapeutic effect of antipsychotics
pholcodine: they may decrease the therapeutic effect of antipsychotics
may have an increasingly adverse effect when combined with Antipsychotic Agents
may have an increased neurotoxic effect when combined with antipsychotic agents
the effects on QT prolongation may be increased
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
The potential for arrhythmogenic effects of mequitazine could be intensified by the presence of antipsychotic agents
Actions and spectrum:Â
Actions: fluspirilene is classified as a typical antipsychotic, and its main mechanism of action is believed to be related to its antagonism of dopamine receptors, particularly D2 receptors, in the brain. This antagonism helps to modulate the activity of dopamine, a neurotransmitter associated with mood, behavior, and cognition. By blocking D2 receptors, fluspirilene reduces the excessive dopamine activity that can contribute to psychotic symptoms.Â
Spectrum: fluspirilene is primarily indicated for the treatment of schizophrenia and other psychotic disorders. It helps to alleviate symptoms such as hallucinations, delusions, disorganized thinking, and agitation. Its antipsychotic effects are used to manage acute episodes of psychosis and may also be employed as maintenance therapy to prevent relapse.Â
Frequency not definedÂ
dystoniaÂ
tardive dyskinesiaÂ
Neuroleptic malignant syndromeÂ
GI disturbancesÂ
antimuscarinic symptomsÂ
ECG changesÂ
Parkinsonian symptomsÂ
akathisiaÂ
nasal congestionÂ
blood dyscrasiasÂ
rashesÂ
conjunctivaÂ
jaundiceÂ
Black Box Warning:Â
There is no specific black box warning associated with fluspirileneÂ
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Comorbidities:Â
Pregnancy consideration: Pregnancy Category not assignedÂ
Lactation: excreted in breast milk: unknown Â
Pregnancy category:Â
Pharmacology:Â
fluspirilene is a typical antipsychotic medication with a mechanism of action primarily centered on its interaction with dopamine receptors in the brain. It exerts its antipsychotic effects by antagonizing dopamine D2 receptors, which helps to modulate the excessive dopamine activity associated with psychotic symptoms. By blocking these receptors, fluspirilene helps to alleviate hallucinations, delusions, and disorganized thinking.
Additionally, fluspirilene’s effects on other neurotransmitter systems, including serotonin and noradrenaline, may contribute to its therapeutic actions. The medication has a long half-life, allowing for sustained activity and dosing intervals. However, like other antipsychotics, fluspirilene can also lead to side effects related to its impact on other receptor systems, such as extrapyramidal symptoms and anticholinergic effects. Monitoring and individualized dosing are essential to achieve the desired therapeutic effects while minimizing potential adverse reactions. Â
Pharmacodynamics:Â
Pharmacokinetics:Â
AbsorptionÂ
fluspirilene is typically administered orally in the form of tablets or capsules. It undergoes slow and variable absorption from the gastrointestinal tract. Its absorption may be influenced by factors such as food intake, which can affect the rate and extent of absorption. After oral administration, fluspirilene is gradually absorbed into the bloodstream.Â
DistributionÂ
fluspirilene has a high binding affinity for plasma proteins, particularly albumin. It is extensively distributed throughout the body, including the central nervous system, where it exerts its antipsychotic effects. Due to its lipophilic nature, fluspirilene can cross the blood-brain barrier.Â
MetabolismÂ
fluspirilene undergoes extensive metabolism primarily in the liver. It is metabolized by various hepatic enzymes, including cytochrome P450 (CYP) enzymes, into several metabolites. The main metabolites of fluspirilene include the sulfoxide and the 4-hydroxy derivative. These metabolites are then further metabolized and eventually eliminated from the body.Â
Elimination and excretionÂ
fluspirilene and its metabolites are primarily eliminated through the feces. Renal excretion plays a minor role in the elimination of fluspirilene. The elimination half-life of fluspirilene is long, ranging from several days to over a week, which contributes to its sustained therapeutic effects and less frequent dosing.Â
Administration:Â
Patient information leafletÂ
Generic Name: fluspirileneÂ
Pronounced: (floo-SPYE-ri-leen)Â Â
Why do we use fluspirilene?Â